Bevacizumab ELISA Kit (ab237642)
Key features and details
- Sensitivity: 30 ng/ml
- Range: 30 ng/ml - 1000 ng/ml
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Quantitative
- Reacts with: Human
Overview
-
Product name
Bevacizumab ELISA Kit
See all Bevacizumab kits -
Detection method
Colorimetric -
Precision
Intra-assay Sample n Mean SD CV% Overall < 30% Inter-assay Sample n Mean SD CV% Overall < 30% -
Sample type
Serum, Plasma -
Assay type
Quantitative -
Sensitivity
30 ng/ml -
Range
30 ng/ml - 1000 ng/ml -
Recovery
Sample specific recovery Sample type Average % Range Serum 70% - 130% -
Assay duration
Multiple steps standard assay -
Species reactivity
Reacts with: Human -
Product overview
Note: Bevacizumab ELISA kit ab237642 is intended for Research Use Only, not for use in diagnostic procedures.
This kit is a sandwich based ELISA kit. The color developed is proportional to the amount of Bevacizumab in the sample or standard. Results of samples can be determined directly using the standard curve.
-
Notes
This product is manufactured by BioVision, an Abcam company and was previously called E4373 BioSim™ Bevacizumab (Human) ELISA Kit. E4373-100 is the same size as the 96 test size of ab237642.
-
Platform
Microplate
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Components 96 tests 96 tests Assay Buffer 2 x 50ml 2 x 50ml Bevacizumab Standard S1 (100 µg/mL) 1 x 300µl 1 x 300µl Bevacizumab Standard S2 (30 µg/mL) 1 x 300µl 1 x 300µl Bevacizumab Standard S3 (10 µg/mL) 1 x 300µl 1 x 300µl Bevacizumab Standard S4 (3 µg/mL) 1 x 300µl 1 x 300µl Bevacizumab Standard S5 (0 µg/mL) 1 x 300µl 1 x 300µl Bevacizumab Standard S6 (High Control) 1 x 300µl 1 x 300µl Bevacizumab Standard S7 (Low Control) 1 x 300µl 1 x 300µl HRP-conjugate Probe 1 x 12ml 1 x 12ml Micro ELISA Plate 1 unit 1 unit Plate sealers 2 units 2 units Stop Solution 1 x 12ml 1 x 12ml TMB substrate 1 x 12ml 1 x 12ml Wash Buffer (20X) 1 x 50ml 1 x 50ml -
Relevance
Bevacizumab is a recombinant human IgG1 monoclonal antibody specific for all human vascular endothelial growth factor-A (VEGF-A) isoforms. The humanized anti-VEGF monoclonal antibody, bevacizumab, has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. The pharmacokinetic properties of bevacizumab in several species have been previously described and are consistent with a typical humanized monoclonal antibody. It was shown in the literature that the surveillance of circulating concentration during maintenance therapy represents a direct and/or indirect factor for some other side effects. Identification of biomarkers for (non-)response and risk factors for adverse drug reactions that might be related to serum concentrations and maintaining the effective concentration of Bevacizumab in order to potentially avoid some side effects with a reliable method might be beneficial.
Images
Datasheets and documents
-
SDS download
-
Datasheet download
References (1)
ab237642 has been referenced in 1 publication.
- Tanaka T et al. Case report: Changes in serum bevacizumab concentration in a hemodialysis patient with unresectable colorectal cancer treated with FOLFIRI plus bevacizumab. Front Oncol 12:947013 (2022). PubMed: 36110939